Here's Why GlycoMimetics Is Soaring 24.3% Higher Today
After unveiling updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML), GlycoMimetics (NASDAQ: GLYC) shares are surging 24.3% as of noon EST Tuesday.
In June, GlycoMimetics provided results for GMI-1271 at the American Society of Clinical Oncology (ASCO) annual meeting. At the time, results from this phase 1/2 study failed to impress, causing shares to sell-off.
Image source: Getty Images.
Source: Fool.com
Glycomimetics Inc. Stock
€0.21
-5.480%
Currently there is a rather positive sentiment for Glycomimetics Inc. with 5 Buy predictions and 3 Sell predictions.
Based on the current price of 0.21 € the target price of 7 € shows a potential of 3281.64% for Glycomimetics Inc. which would more than double the current price.
